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The most used biological markers in HIV patients are the CD4
count1 and HIV-1 RNA level,1 as they are independent predictors of
survival. Other markers of disease severity are clinical manifesta-
tions,2 compliance to treatment,3 and hematological alterations.4
These alterations are due to many factors including the direct
effect of HIV on hematopoietic cells, opportunistic infections,
drugs, and chronic inﬂammation.4 Anemia is the most common
hematological abnormality in HIV patients and has been shown to
be associated with disease progression.5 It is usually normocytic
and normochromic, with a low reticulocyte level.6 Almost 95% of
HIV patients present anemia during the course of the disease.5
Furthermore, it has been demonstrated that anemia is associated
with increased mortality, and that mortality decreases when
anemia is resolved.5,7 This characterizes hemoglobin concentra-
tion (Hb) as an independent mortality factor, regardless of the
baseline CD4 count.5 The objective of the current study was to
evaluate the impact of Hb increment on mortality in HIV patients.
We reviewed the data of 701 consecutive HIV patients followed
at our institution between August and November 2009.6 Among
these patients, 261 had anemia (Hb < 12.0 g/dl for women and
<14.0 g/dl for men). Hb of 167 patients was registered 3 months
after the ﬁrst evaluation. After 2 years of follow-up, the number of
deaths was recorded. Statistical analyses were performed using SAS
version 9.1 (SAS Institute Inc., Cary, NC, USA). A p-value of less than
0.05 was considered signiﬁcant.
A total of 83 patients presented Hb increments (median 0.9 g/
dl; range 0.1–5.6 g/dl), of whom only six died. In parallel, 27 deaths
were seen in the group of 84 patients who had no increment (odds
ratio 6.079; conﬁdence interval 2.354–15.7; p < 0.0001) (Figure 1).
Anemia is the most common hematological abnormality
observed in HIV patients.5 It is associated with a reduced quality
of life and an increased disease severity.5,7 Hemoglobin level is a
marker of severity in a number of diseases, such as cancer.8 In HIV0 200 400 600 800
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Figure 1. Kaplan–Meier curve of survival for HIV patients by hemoglobin
increment.
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can be seen in this study, the persistence of anemia for more than
3 months identiﬁes a group of patients with a higher death rate.
In conclusion, patients whose Hb increased showed a signiﬁ-
cantly reduced mortality. Once it becomes an inexpensive and
sensitive test, accessible to emergent countries, the determination
of Hb could be a useful marker of disease progression and severity,
and permit the identiﬁcation of a group of patients more
vulnerable to complications who deserve special care.
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